accord
free
drug
hypothesi
unbound
drug
avail
act
physiolog
site
action
import
plasma
protein
bind
primarili
resid
impact
pharmacokinet
pharmacodynam
major
plasma
protein
glycoprotein
aag
repres
intrigu
one
primarili
due
high
affin
low
capac
properti
protein
addit
mark
speci
age
differ
protein
express
homolog
drug
bind
affin
thorough
understand
drug
bind
aag
help
aid
improv
translat
pharmacokineticpharmacodynam
pkpd
relationship
preclin
speci
human
well
adult
neonat
review
provid
comprehens
overview
current
understand
biochemistri
aag
endogen
function
impact
diseas
util
biomark
impact
pkpd
experiment
consider
discuss
well
recommend
understand
potenti
impact
aag
pk
drug
discoveri
earli
develop
accord
free
drug
hypothesi
unbound
drug
avail
act
physiolog
site
action
whether
intend
pharmacolog
target
action
undesir
site
potenti
toxicolog
consequ
import
plasma
protein
bind
primarili
resid
impact
pharmacokinet
properti
clearanc
cl
volum
distribut
v
ss
serum
albumin
lipoprotein
acid
glycoprotein
aag
major
protein
involv
sequest
drug
plasma
aag
also
known
orosomucoid
orm
member
acut
phase
protein
app
famili
first
describ
singl
polypeptid
chain
consist
amino
acid
five
glycan
chain
account
total
molecular
weight
kda
aag
form
primarili
liver
circul
mgml
plasma
healthi
human
level
healthi
anim
gener
lower
compar
healthi
human
tabl
diseas
state
includ
inflamm
infect
cancer
aag
level
increas
human
show
much
broader
fold
induct
anim
depend
anim
speci
diseas
tabl
biolog
role
aag
remain
unclear
demonstr
regul
immun
play
role
proand
antiinflammatori
respons
aag
long
use
clinic
biomark
potenti
expand
c
n
c
e
r
infect
applic
diseas
diagnosi
prognosi
character
grown
given
recent
advanc
proteom
high
resolut
mass
spectrometri
aag
repres
rel
small
portion
total
plasma
protein
compar
composit
albumin
play
signific
role
drug
bind
pharmacokinet
pk
aag
consid
high
affinitylow
capac
plasma
protein
wherea
albumin
consid
low
affinityhigh
capac
aag
highli
acid
protein
low
isoelectr
point
pi
rang
properti
enabl
aag
bind
mainli
basic
drug
ie
lidocain
propranolol
verapamil
may
also
bind
neutral
lipophil
molecul
ie
steroid
hormon
acid
drug
ie
phenobarbit
wherea
albumin
mostli
implic
bind
latter
charg
type
drug
bind
plasma
protein
vari
degre
affin
extens
variabl
sialyl
aag
drive
low
wide
pi
rang
properti
impact
drug
affin
ultim
pk
sinc
aag
level
increas
diseas
state
drug
high
affin
may
demonstr
higher
bind
lower
fraction
unbound
f
u
alter
pk
properti
eg
lower
total
cl
lower
v
ss
given
known
speci
differ
aag
abund
drug
affin
grow
bodi
work
pk
preclin
speci
accur
predict
pk
human
sever
case
studi
discuss
herein
incorpor
ontogeni
aag
may
also
enabl
accur
predict
pk
neonat
infant
patient
provid
rational
test
extent
affin
drug
bind
aag
albumin
drug
discoveri
process
aid
prospect
human
pk
predict
effort
fig
research
still
lag
character
higher
speci
aag
could
help
better
predict
pk
human
furthermor
experiment
factor
emerg
critic
accur
determin
aagdrug
bind
vitro
aspect
also
discuss
review
albumin
aag
lipoprotein
consid
relev
plasma
protein
term
drug
bind
rang
albumin
level
slightli
lower
anim
compar
human
level
aag
also
rel
lower
anim
compar
human
healthi
state
level
much
variabl
diseas
set
describ
tabl
human
albumin
aag
level
tabl
ii
provid
unit
mgml
serv
quick
refer
consid
stoichiometri
drug
concentr
assum
singl
drug
bind
site
model
gener
rodent
mgml
minipig
mgml
aag
valu
lower
compar
human
tabl
except
gener
report
mice
howev
explan
suggest
author
dog
aag
demonstr
highli
variabl
level
mgml
though
gener
lower
mean
valu
mgml
report
littl
character
monkey
aag
literatur
though
also
report
lower
cynomolgu
monkey
mgml
compar
human
convent
pig
speci
aag
level
report
higher
mgml
compar
human
howev
find
consist
observ
lower
aag
valu
mgml
mgml
also
report
convent
pig
speci
aag
behav
posit
acut
phase
protein
app
increas
respons
stimuli
includ
infect
inflamm
cancer
tabl
acut
phase
respons
apr
consid
part
innat
nonspecif
defens
system
offer
protect
prior
adapt
specif
immun
respons
magnitud
respons
differ
across
speci
diseas
set
minor
moder
major
aap
character
increas
protein
express
respect
mice
aag
consid
major
posit
app
level
increas
follow
stimuli
wherea
human
respons
rel
moder
increas
fold
domest
cat
aag
increas
moder
fold
oncolog
set
wherea
robust
respons
report
infect
mix
respons
report
convent
pig
minipig
convent
pig
aag
shown
behav
neg
app
level
declin
normal
valu
posit
app
respons
infect
inflamm
level
increas
convent
pig
minipig
aag
respons
follow
acut
stimuli
lp
turpentin
inject
despit
increas
app
convent
pig
minipig
creactiv
protein
crp
serum
amyloid
saa
haptoglobin
hp
pig
major
acut
phase
protein
pmap
christoffersen
et
al
hypothes
aag
respons
minipig
may
differ
sensit
acut
versu
chronic
set
observ
previous
report
app
saa
hp
cattl
chronic
inflammatori
set
obes
mildli
diabet
minipig
fed
high
fat
diet
elev
aag
level
chang
hous
condit
also
caus
increas
aag
minipig
well
increas
crp
saa
hp
pmap
unclear
level
return
baselin
find
consid
acclim
experiment
design
data
interpret
neither
neg
app
respons
lp
insensit
porcin
aag
report
speci
date
howev
unpreced
given
app
behav
differ
across
speci
exampl
crp
saa
consid
major
posit
app
human
pig
crp
saa
affect
mice
rat
respect
anoth
exampl
differenti
speci
respons
transferrin
act
neg
app
human
posit
app
mice
mix
report
regard
gender
differ
aag
level
may
statist
differ
rel
modest
compar
differ
observ
diseas
development
set
booker
et
al
report
statist
signific
differ
aag
level
newborn
human
male
mgml
femal
mgml
tabl
iii
opposit
trend
observ
adult
human
aag
level
mgml
male
femal
respect
similarli
blain
et
al
report
slightli
lower
level
human
male
mgml
compar
femal
mgml
femal
minipig
gener
slightli
lower
though
overlap
rang
aag
level
compar
male
gender
differ
observ
dog
aag
level
mgml
ontogeni
aag
level
rang
undetect
develop
human
fetu
mgml
cord
blood
mgml
birth
steadili
increas
mgml
month
achiev
adult
level
mgml
month
age
tabl
iv
similarli
aag
undetect
mgml
cord
blood
dog
thu
significantli
lower
compar
adult
dog
mgml
opposit
trend
observ
convent
pig
mgml
report
fetal
pig
mgml
day
newborn
mgml
week
old
mgml
adult
consist
pattern
heegaard
et
al
report
aag
level
mgml
newborn
pig
day
old
declin
mgml
adult
aag
compris
total
plasma
protein
newborn
pig
wherea
adult
pig
properti
report
minipig
laboratori
anim
date
limit
data
publish
fetal
neonat
plasma
level
aag
speci
howev
liver
aag
level
rat
also
shown
vari
develop
pregnanc
also
impact
aag
level
human
aag
level
lower
pregnant
femal
continu
declin
throughout
pregnanc
birth
begin
climb
back
prepregn
valu
wood
wood
report
valu
femal
nonpregn
healthi
volunt
pregnant
women
howev
studi
size
rel
small
n
opposit
report
pregnant
dog
rhesu
monkey
aag
level
higher
pregnant
anim
respect
given
strike
differ
fetal
newborn
adult
aag
level
may
import
understand
placent
transfer
milk
plasma
ratio
mp
drug
bind
aag
fleishak
mcnamara
describ
diffusion
model
assess
drug
distribut
milk
show
vitro
drug
bind
serum
milk
protein
reason
predict
mp
drug
ratio
vivo
author
test
model
lactat
rabbit
use
propranolol
compound
known
bind
high
affin
aag
mimic
diseas
set
rabbit
dose
bovin
aag
propranolol
pk
paramet
evalu
diffusion
model
abl
accur
predict
decreas
propranolol
mp
aag
administr
importantli
roughli
proport
reduct
total
plasma
cl
counteract
decreas
f
u
maintain
consist
cl
u
rate
total
drug
level
milk
improv
predict
f
u
human
infant
mcnamara
alcorn
consid
ratio
aag
albumin
cord
blood
newborn
adult
blood
correspond
ratio
aag
albumin
employ
mgml
cord
divid
mgml
adult
mgml
cord
divid
mgml
adult
predict
f
u
newborn
better
drug
predominantli
bind
albumin
averag
predict
observ
ratio
newbornadult
f
u
respect
drug
predominantli
bind
albumin
n
drug
studi
set
averag
predict
observ
ratio
newbornadult
f
u
respect
drug
predominantli
bind
aag
n
drug
studi
set
major
drug
f
u
newborn
underpredict
drug
predominantli
bind
aag
albumin
respect
possibl
explan
dispar
suggest
author
includ
chang
drugligand
affin
associ
age
well
increas
free
fatti
acid
bilirubin
newborn
contribut
decreas
drug
bind
addit
predict
may
due
inaccur
fals
high
aag
albumin
newborn
level
employ
model
aag
level
gener
variabl
higher
dynam
rang
compar
albumin
alon
explain
trend
predict
three
gene
aaga
aagb
locat
chromosom
encod
human
aag
haag
aaga
encod
express
liver
aagb
aagb
ident
structur
differ
aaga
amino
acid
encod
aag
share
signific
homolog
human
immunoglobulin
g
igg
epiderm
growth
factor
egf
bind
domain
egf
receptor
aaga
polymorph
three
close
relat
genet
variant
differ
amino
acid
residu
gener
refer
tabl
v
aagb
encod
genet
variant
individu
possess
mixtur
variant
common
phenotyp
follow
molar
ratio
healthi
individu
ratio
increas
diseas
set
sinc
variant
induc
gender
relat
differ
observ
express
variant
form
xray
crystallographi
show
two
common
bind
pocket
lobe
variant
variant
possess
uniqu
third
lobe
make
promiscu
drug
bind
drug
bind
properti
shown
differ
amongst
variant
exampl
basic
drug
imipramin
shown
bind
strongli
variant
wherea
warfarin
strongli
variant
drug
bind
genet
variant
well
character
sinc
protein
bind
studi
routin
conduct
pool
suppli
healthi
human
plasma
whole
plasma
individu
subjectspati
protein
routin
undergo
posttransl
modif
impact
physiolog
function
halflif
glycosyl
addit
oligosaccharid
chain
glycan
one
abund
posttransl
modif
incid
eukaryot
protein
aap
particularli
suscept
glycosyl
glycosyltransferas
glycosidas
respons
build
precursor
glycan
process
highli
vulner
chang
diseas
state
oligosaccharyltransferas
transfer
glycan
polypeptid
chain
asparagin
nlink
serinethreonin
olink
residu
former
exhibit
common
pentasaccharid
core
glycan
bond
occur
either
configur
allow
structur
divers
antiinflammatori
immunomodulatori
properti
directli
impact
glycan
composit
turn
chang
throughout
variou
stage
inflamm
heavili
sialyl
glycan
make
aag
one
acid
plasma
protein
high
level
heterogen
result
low
wide
pi
rang
turn
impact
drug
bind
aag
desialyl
result
increas
pi
rang
human
aag
contain
nlink
glycan
polypeptid
backbon
form
varieti
bi
tri
tetrabranch
potenti
express
sialic
acid
moieti
despit
thousand
potenti
uniqu
glycan
combin
associ
aag
glycan
combin
observ
plasma
healthi
human
howev
diseas
state
mani
glycan
modif
detect
regul
inflammatori
cytokin
tumor
necrosi
factor
util
biomark
describ
later
aag
offer
two
drug
bind
site
basic
drug
one
acid
drug
steroid
drug
bind
aag
reportedli
mediat
predominantli
via
hydrophob
interact
data
suggest
potenti
electrostat
interact
evid
support
latter
includ
observ
stereoselect
bind
propranolol
isom
desialyl
lower
plasma
ph
shown
decreas
drug
bind
aag
propranolol
bind
reduc
progesteron
bind
unchang
desialyl
aag
homolog
aag
gene
observ
across
mammal
includ
rodent
cat
dog
pig
monkey
human
tabl
vi
mous
rat
rabbit
pig
aag
gene
homolog
respect
human
aag
three
human
aag
gene
one
gene
report
rat
two
three
mous
depend
strain
sourc
despit
presenc
multipl
two
disulfid
bridg
describ
human
pig
aag
one
rat
variou
bind
site
character
across
speci
human
acid
basic
steroid
bind
site
report
wherea
cow
dog
lack
acid
bind
site
aag
belong
famili
app
mainli
gener
liver
parenchym
cell
elev
level
within
h
injuri
ie
infect
inflamm
burn
cancer
app
definit
protein
chang
respons
injuri
plasma
exampl
posit
app
includ
ceruloplasmin
aag
serum
amyloid
saa
increas
level
human
respect
diseas
state
neg
app
includ
albumin
transferrin
insulinlik
growth
factor
modestli
declin
plasma
diseas
state
aag
member
lipocalin
superfamili
extracellular
transport
bind
transport
small
hydrophob
endogen
exogen
chemic
upregul
app
enhanc
local
inflamm
aid
recognit
microb
direct
leukocyt
increas
blood
flow
site
insult
minim
inflammatori
respons
elsewher
rapid
high
magnitud
respons
well
short
properti
characterist
app
hypothes
key
element
innat
immun
homeostasi
kept
check
redund
given
app
may
impact
multipl
pathway
multipl
app
may
provid
overlap
biolog
function
inflammatori
cytokin
shown
regul
aag
addit
app
includ
creactiv
protein
crp
haptoglobin
hp
saa
hemopexin
function
aag
still
poorli
understood
howev
part
cytokin
mediat
feedback
mechan
implic
antiand
proinflammatori
modul
monocyt
activ
induct
tcell
prolifer
well
activ
secret
associ
proinflammatori
role
aag
su
et
al
propos
posit
feedback
mechan
app
wherebi
inflamm
amplifi
respons
synthesi
aagstimul
monocyt
viceversa
antiinflammatori
role
aag
also
report
aag
inhibit
neutrophil
chemotact
respons
associ
stimul
nformylmethionylleucylphenylalanin
fmlp
inflammatori
peptid
complement
compon
aag
shown
modul
releas
free
radic
regardless
treatment
time
whether
aag
introduc
prior
post
neutrophil
activ
multipl
vivo
septic
shock
model
rodent
demonstr
protect
effect
aag
dose
prophylact
anim
challeng
endotoxin
role
aag
angiogenesi
studi
use
ex
vivo
rat
model
follow
aortic
excis
macrophag
respond
rapidli
within
minut
increas
level
peak
h
remain
elev
throughout
angiogenesi
guid
overexpress
aag
within
h
level
peak
day
sharpli
declin
thereaft
inflamm
aag
proand
antiangiogen
effect
depend
context
earli
angiogenesi
process
aag
play
inhibitori
role
via
modul
mitogenactiv
protein
kinas
wherea
later
process
aag
promot
angiogenesi
via
vascular
endotheli
growth
factor
regul
app
level
aag
typic
increas
within
h
injuri
begin
declin
sever
day
post
amelior
increas
aag
level
report
serum
breast
lung
ovarian
cancer
patient
studi
compar
aag
level
lung
cancer
patient
versu
individu
known
cancer
result
show
sensit
specif
aag
level
correl
relapsefre
surviv
case
hepatocellular
carcinoma
hcc
diagnosi
challeng
due
liver
condit
ie
cirrhosi
present
similar
abnorm
howev
increas
aag
level
pronounc
hcc
provid
potenti
basi
differenti
diseas
proport
breast
cancer
patient
increas
aag
level
increas
diseas
progress
exampl
stage
ii
iv
patient
respect
elev
level
compar
healthi
donor
diseas
state
aag
modifi
quantit
describ
well
qualit
phenomenon
describ
alminquist
laus
compar
serum
glycoprotein
cancer
patient
versu
healthi
donor
rel
associ
polypeptid
backbon
heterogen
glycan
composit
structur
make
good
system
character
correl
diseas
state
commonli
exploit
glycoprotein
use
clinic
cancer
biomark
test
includ
carcinoembryon
antigen
cea
cancer
antigen
prostatespecif
antigen
psa
diagnosi
colorect
ovarian
pancreat
prostat
cancer
respect
technolog
advanc
mass
spectrometri
proteom
led
improv
understand
glycan
structur
function
glycan
rel
abund
compar
associ
protein
often
time
multipl
copi
per
glycoprotein
case
aag
known
associ
glycan
depend
speci
tabl
vi
associ
cancer
tissu
also
detect
serum
make
use
biomark
feasibl
clinic
set
addit
modifi
glycan
may
associ
one
glycoprotein
afford
multipl
opportunitiespattern
detect
modif
glycan
associ
biomark
rel
specif
select
epitop
allow
accur
mean
distinguish
healthi
versu
diseas
tissu
diseas
progress
exampl
test
serum
level
modifi
glycan
associ
psa
enabl
distinct
benign
prostat
hypertrophi
cancer
prostat
breast
cancer
serum
glycosyl
pattern
distinguish
healthi
diseas
tissu
also
differenti
malign
nonmalign
tumor
diseas
stage
inflammatori
diseas
includ
rheumatoid
arthriti
asthma
aag
glycan
branch
compar
healthi
subject
patient
suffer
acut
inflamm
infect
burn
tissu
damag
show
asialyl
carbohydratedefici
variant
aag
human
aag
rel
short
day
compar
albumin
day
aag
turnov
depend
sialic
acid
residu
termin
galactos
group
mccurdi
studi
impact
glycosyl
vivo
cl
human
deriv
aag
rabbit
follow
intraven
inject
termin
nativ
human
aag
h
consist
valu
h
report
regoeczi
et
al
alteredreduc
absenc
glycosyl
lower
h
h
respect
cl
nativ
aag
mlhkg
wherea
much
higher
valu
observ
aag
form
alter
mlhkg
absent
glycosyl
mlhkg
steadyst
volum
distribut
v
ss
mlkg
nativ
aag
wherea
much
higher
valu
observ
alter
mlkg
absent
glycosyl
mlkg
absenc
reduct
alter
nlink
glycosyl
result
mark
increas
renal
elimin
compar
nativ
aag
studi
support
disposit
properti
aag
depend
diseas
state
sinc
biochemistri
aag
alter
diseas
describ
earlier
therefor
given
drug
bind
aag
high
extent
possibl
underli
differ
pk
drug
healthi
diseas
popul
may
attribut
aag
drug
bind
plasma
tissu
intend
target
critic
paramet
predict
pk
pharmacodynam
pd
howev
optim
protein
bind
plasma
drug
discoveri
set
scientif
unsound
nearli
fda
approv
drug
prior
classifi
highli
bound
f
u
trend
increas
recent
year
new
drug
classifi
highli
bound
f
u
free
drug
hypothesi
describ
free
concentr
drive
activ
cross
cellular
membran
reach
target
focu
optim
cl
u
permeabl
describ
albumin
aag
lipoprotein
consid
import
plasma
protein
involv
drug
bind
albumin
higher
drug
capac
due
rel
abund
plasma
aag
level
lower
high
affin
drug
satur
may
occur
satur
aag
may
may
buffer
albumin
depend
drug
bind
affin
albumin
plasma
protein
level
chang
diseas
state
decreas
albumin
increas
aag
gener
observ
may
impact
protein
bind
pk
albumin
aag
level
significantli
lower
newborn
newborn
adult
ratio
respect
factor
consid
predict
pk
young
pediatr
popul
propos
flowchart
ascertain
impact
aag
potenti
covari
pk
variabl
earli
drug
develop
shown
fig
routin
screen
human
laboratori
anim
speci
singl
low
concentr
typic
perform
earli
drug
discoveri
pk
data
preclin
speci
acquir
program
advanc
toward
develop
candid
select
preliminari
project
human
pk
dose
valu
assess
concentr
depend
ident
major
plasma
protein
involv
drug
bind
extent
bind
high
bound
singl
concentr
assay
condit
character
bind
constant
aag
albumin
warrant
particularli
human
free
fraction
lower
rel
anim
concentr
depend
observ
high
affin
human
aag
may
worthwhil
assess
k
speci
build
addit
confid
human
pk
predict
multipl
routin
vitro
analyt
procedur
exist
assess
extent
affin
drug
bind
protein
recent
publish
industri
white
paper
di
et
al
provid
comprehens
review
commonli
use
proteinbind
practic
challeng
recommend
intent
section
manuscript
suggest
use
control
compound
describ
sourc
erron
fraction
unbound
valu
overlook
assay
good
practic
includ
control
compound
assess
along
test
compound
ensur
properli
function
assay
data
control
compound
avail
given
assayspeci
one
still
monitor
valu
control
time
ensur
consist
conduct
definit
assay
use
multipl
control
compound
advis
sinc
multipl
factor
influenc
bind
compound
specif
literatur
valu
propranolol
warfarin
summar
across
speci
tabl
vii
intent
provid
refer
accept
free
fraction
valu
control
compound
across
speci
propranolol
select
moder
high
bind
human
plasma
protein
howev
affin
higher
aag
rel
albumin
approxim
two
order
magnitud
therefor
propranolol
serv
control
compound
preferenti
bind
aag
report
propranolol
f
u
valu
rang
human
plasma
differ
outsid
typic
deem
normal
assay
variabl
accept
assay
f
u
valu
propranolol
within
healthi
human
plasma
warfarin
select
highli
bound
aag
albumin
ge
life
scienc
applic
note
help
includ
highli
bound
control
compound
sinc
gener
requir
longer
incub
time
achiev
equilibrium
report
warfarin
f
u
valu
rang
human
plasma
differ
absolut
differ
low
major
refer
indic
narrow
rang
therefor
accept
assay
f
u
valu
warfarin
within
rang
similar
report
recent
publish
white
paper
advis
select
compound
moder
low
protein
bind
serv
control
f
u
valu
gener
variabl
base
recent
studi
possibl
larg
rang
human
f
u
valu
due
blood
collect
storag
procedur
clinic
set
f
u
typic
measur
plasma
serum
patient
blood
collect
vacutain
collect
procedur
storag
blood
signific
impact
protein
bind
result
long
report
plastic
disrupt
bind
drug
aag
exampl
plastic
tri
phosphat
tbep
use
soften
rubber
stopper
vacutain
shown
disrupt
aag
bind
basic
drug
lidocain
quinidin
polyvinyl
chlorid
pvc
bag
contain
plastic
diethylhexyl
phthalat
dehp
routin
use
blood
collect
butler
et
al
report
averag
twofold
increas
f
u
drug
known
bind
aag
blood
collect
pvc
bag
versu
blood
collect
vacutain
recent
experi
conduct
show
correl
dehp
level
chang
f
u
drug
bind
aag
blood
immedi
transfer
bag
vacutain
dehp
level
low
steadili
increas
storag
day
day
dehp
easili
leach
content
bag
sinc
chemic
bound
pvc
expect
f
u
higher
drug
known
bind
aag
test
use
plasma
contain
high
level
dehp
shift
f
u
significantli
reduc
though
elimin
blood
immedi
transfer
vacutain
result
gener
use
blood
product
collectedstor
plastic
contain
bag
interpret
caution
f
u
valu
may
overestim
true
vivo
valu
instanc
protein
bind
measur
clinic
vacutain
nominim
dehp
exposur
use
sinc
small
ml
blood
volum
collect
contrast
rel
larger
volum
ml
collect
bag
donat
andor
nonclin
research
purpos
note
blood
anim
typic
collect
smaller
vessel
contain
dehp
therefor
overestim
f
u
less
like
occur
anim
blood
studi
may
warrant
assess
effect
drug
bind
commerci
avail
vacutain
precaut
despit
report
literatur
decad
bag
contain
plastic
known
disrupt
aagdrug
bind
continu
wide
use
blood
collect
intend
use
research
clinic
set
dehp
essenti
maintain
shelf
life
blood
product
day
protect
membran
red
blood
cell
transfus
recipi
routin
receiv
blood
collect
store
bag
clinic
effect
regard
drug
displac
report
blood
collect
bag
develop
though
unclear
effect
aagdrug
bind
multipl
class
drug
report
bind
aag
exampl
relationship
aag
bind
lipid
solubl
andor
electrostat
interact
report
benzodiazepin
phenothiazin
neurolept
beta
blocker
anthracyclin
deriv
antihistamin
analges
focu
sever
wellstudi
exampl
drugaag
bind
affect
pk
andor
pd
clinic
oncolog
set
vismodegib
approv
treatment
metastat
basal
cell
carcinoma
food
drug
administr
fda
pk
characterist
exhibit
phase
clinic
trial
unexpect
base
preclin
allometr
scale
follow
singl
oral
dose
exposur
higher
predict
low
appar
cl
long
day
cross
speci
vitro
data
show
high
plasma
protein
bind
bound
low
metabol
turnov
hepatocyt
speci
except
monkey
agre
well
vivo
cl
valu
mechanist
pk
model
employ
explain
role
plasma
protein
bind
solubilitylimit
absorpt
low
metabol
cl
contribut
unusu
clinic
pk
properti
vitro
studi
reveal
far
lower
vismodegib
solubl
mgml
higher
ph
rang
compar
mgml
ph
impact
solubl
manifest
satur
oral
absorpt
increas
mean
steadyst
concentr
c
ss
increas
oral
dose
mg
respect
free
fraction
vismodegib
remain
constant
across
dose
group
howev
separ
studi
increas
free
fraction
vismodegib
report
singl
mg
dose
versu
repeat
daili
mg
dose
vismodegib
plasma
protein
bind
properti
character
isotherm
titrat
calorimetri
itc
surfac
plasmon
reson
spr
procedur
show
higher
vismodegibaag
affin
human
isoform
rel
rat
isoform
itc
k
valu
vismodegibaag
human
rat
respect
spr
k
valu
vismodegibaag
detect
human
rat
respect
wherea
k
valu
vismodegibalbumin
similar
human
rat
respect
vitro
experi
show
neg
correl
aag
concentr
target
engag
wherebi
supplement
physiolog
relev
concentr
aag
result
dampen
hh
signal
via
report
assay
high
correl
r
slope
aag
total
vismodegib
c
ss
plasma
sampl
cancer
patient
suggest
role
plasma
protein
bind
vismodegib
drug
disposit
perhap
even
compel
intrapati
parallel
chang
total
vismodegib
concentr
chang
aag
correl
found
albumin
level
vismodegib
concentr
satur
aag
propos
key
determin
nonlinear
pk
vismodegib
given
aag
high
affinitylow
capac
protein
near
stoichiometr
level
vismodegib
aag
report
despit
high
affin
result
low
free
fraction
remain
suffici
unbound
vismodegib
avail
interact
target
demonstr
pharmacolog
effect
order
understand
mechan
nonlinear
pk
healthi
human
subject
receiv
either
singl
oral
dose
daili
oral
dose
mg
vismodegib
follow
iv
microtrac
dose
c
vismodegib
h
post
first
last
day
oral
dose
aag
level
within
close
rang
two
dose
group
elimin
need
correct
cl
v
ss
valu
singl
iv
dose
mlh
l
roughli
lower
depend
number
speci
employ
model
lower
respect
compar
preclin
allometr
scale
predict
rel
day
cl
v
ss
increas
respect
day
remain
unchang
day
mean
free
fraction
increas
day
oral
dose
compar
singl
dose
find
consist
observ
previous
describ
correct
protein
bind
vismodegib
unbound
cl
v
ss
valu
rel
similar
day
absolut
bioavail
follow
singl
oral
dose
declin
day
repeat
dose
find
attribut
slow
absorpt
limit
intestin
solubl
given
nonlinear
pk
long
phase
ib
clinic
studi
conduct
determin
vismodegib
steadyst
concentr
could
maintain
less
frequent
dose
three
oral
dose
schedul
evalu
mg
daili
qd
weekli
qw
three
time
per
week
tiw
receiv
load
dose
vismodegib
mg
qd
day
steadyst
achiev
altern
dose
schedul
vismodegib
level
declin
qw
tiw
group
rel
qd
howev
declin
unbound
vismodegib
respect
greater
declin
total
vismodegib
respect
qd
dose
schedul
maintain
unbound
vismodegib
concentr
suffici
achiev
target
pathway
inhibit
ic
gliomaassoci
oncogen
previous
describ
therefor
recommend
dose
schedul
maintain
mg
qd
one
addit
point
consider
discrep
vitro
ex
vivo
free
fraction
valu
report
vismodegib
human
plasma
respect
discrep
may
attribut
collect
storag
blood
product
describ
herein
recent
public
free
fraction
valu
increas
sharpli
aagbind
drug
human
blood
expos
plastic
dehp
exampl
vismodegib
free
fraction
increas
collect
vacutain
nominim
plastic
collect
store
bag
contain
plastic
day
respect
addit
vismodegib
free
fraction
increas
human
plasma
spike
plastic
concentr
one
could
expect
measur
blood
sever
week
storag
similar
bag
small
molecul
protein
kinas
inhibitor
singl
agent
clinic
trial
initi
multipl
oncolog
indic
late
follow
combin
studi
anticanc
agent
pk
paramet
preclin
speci
mous
rat
dog
rang
follow
moder
high
cl
roughli
hepat
blood
flow
high
v
ss
lkg
moder
h
clinic
pk
predict
allometri
exhibit
low
cl
mlh
low
v
ss
l
long
h
consid
highli
bound
plasma
protein
preclin
speci
free
fraction
rang
free
fraction
substanti
lower
human
plasma
free
fraction
incub
physiolog
relev
level
haag
mgml
albumin
mgml
respect
show
preferenti
bind
aag
vitro
studi
show
mark
increas
free
fraction
increas
concentr
approach
stoichiometr
level
aag
associ
constant
k
lmol
haag
roughli
equival
k
nm
wherea
dog
k
lower
lmol
sparreboom
et
al
character
role
aag
pk
increas
dose
rang
mgm
day
iv
infus
h
increas
cl
mlh
mlh
respect
linear
increas
v
ss
l
l
respect
less
proport
increas
auc
area
curv
extrapol
infin
mg
hl
cl
trend
r
predos
aag
level
despit
rel
small
data
set
n
propos
increas
cl
human
due
least
part
increas
free
fraction
aag
becom
satur
cl
dog
demonstr
depend
dose
mgkg
find
consist
notabl
differ
k
human
versu
dog
k
roughli
order
magnitud
lower
compar
k
haagvismodegib
addit
appear
bind
significantli
albumin
given
compar
k
valu
aag
vs
human
plasma
vs
lmol
respect
satur
aag
differenti
affin
aag
albumin
like
contribut
nonlinear
pk
vismodegib
k
differ
consider
preclin
speci
lead
poor
predict
accuraci
allometr
method
slow
dissoci
rate
may
reduc
v
ss
hinder
free
drug
target
interact
contrast
preclin
observ
high
v
ss
high
tumor
plasma
ratio
declin
tumor
volum
advanc
clinic
due
unpredict
pk
offtarget
kinas
inhibit
imatinib
select
inhibitor
bcrabl
plateletderiv
growth
factor
receptor
ckit
receptor
tyrosin
kinas
approv
grant
treatment
chronic
myelogen
leukemia
gastrointestin
stromal
tumor
fda
imatinibaag
bind
concentrationdepend
report
k
l
mol
roughli
equival
k
imatinibalbumin
bind
consider
weaker
k
lmol
roughli
equival
k
ad
complex
differenti
bind
imatinib
variou
human
aag
isoform
k
report
variant
wherea
bind
much
weaker
variant
unpublish
data
separ
incub
aag
variant
imatinib
result
free
fraction
respect
imatinib
exhibit
linear
pk
patient
low
oral
cl
rang
lh
long
h
high
oral
bioavail
proport
increas
auc
observ
oral
dose
mg
pk
paramet
similar
singl
repeat
dose
show
accumul
steadyst
correl
imatinib
pk
genotyp
bodi
weight
aag
level
shown
patient
despit
linear
pk
total
imatinib
nonlinear
relationship
exist
free
fraction
total
imatinib
concentr
plasma
result
high
affin
aag
weaker
affin
albumin
elev
level
aag
patient
link
delay
lack
respons
imatinib
treatment
well
potenti
resist
mechan
clinic
studi
cml
patient
approxim
half
exhibit
elev
aag
level
posit
correl
diseas
progress
white
blood
count
chronic
acceler
blast
crisi
phase
diseas
patient
respect
increasingli
like
higher
aag
level
impact
plastic
dehp
imatinib
free
fraction
human
plasma
also
assess
imatinib
free
fraction
increas
collect
vacutain
nominim
plastic
collect
store
bag
contain
plastic
day
respect
addit
imatinib
free
fraction
increas
human
plasma
spike
plastic
plasticizerfre
free
fraction
valu
report
ingram
et
al
similar
report
packag
insert
novarti
pharmaceut
corpor
refer
pinometostat
firstinclass
small
molecul
inhibitor
first
member
novel
histon
methyltransferas
inhibitor
class
enter
phase
clinic
trial
adult
pediatr
mllr
leukemia
patient
consensu
preclin
predict
across
multipl
divers
method
suggest
pinometostat
would
moderatetohigh
cl
compound
human
estim
rang
mlminkg
speciesinvari
time
approach
show
crossspeci
congruenc
timeconcentr
profil
howev
earli
develop
observ
cl
human
shown
markedli
lower
determin
preclin
speci
major
interspeci
scale
allometr
method
overpredict
human
cl
pinometostat
fold
error
rang
character
vertic
allometri
differ
free
fraction
rat
human
provid
basi
improv
predict
use
free
fraction
correct
intercept
fcim
method
unambigu
speci
differ
cl
relat
qualit
differ
metabol
pathway
rout
elimin
instead
crossspeci
differ
plasma
protein
bind
concentr
depend
protein
bind
observ
human
plasma
relev
concentr
rang
less
appar
preclin
speci
along
vitro
kinet
determin
suggest
satur
bind
pinometostat
aag
equilibrium
dissoci
constant
k
pinometostat
bind
human
aag
measur
indic
high
affin
interact
comparison
prototyp
aag
ligand
dipyridamol
disopyramid
thioridazin
k
valu
respect
furthermor
disproportion
higher
express
aag
human
plasma
rel
preclin
speci
like
contribut
factor
alon
irrespect
potenti
speciesspecif
differ
aag
affin
suggest
k
given
drugaag
bind
low
log
order
lower
rel
k
albumin
pk
may
exhibit
nonlinear
drug
also
high
affin
albumin
high
capac
protein
fluctuat
free
fraction
minim
drug
low
affin
albumin
nonlinear
effect
may
exacerb
drug
level
near
stoichiometr
aag
sinc
aag
low
capac
protein
may
becom
satur
given
known
differ
abund
homolog
across
speci
aag
allometr
scale
may
suitabl
human
pk
predict
differ
k
someth
easili
measur
vitro
aag
preclin
speci
commerci
avail
though
still
limit
suppli
monitor
aag
andor
free
drug
concentr
well
phenotyp
genet
variant
aag
patient
may
warrant
special
circumst
better
understand
pk
pd
fig
propos
flowchart
incorpor
protein
bind
assess
drug
research
develop
investig
ongo
propos
reliabl
procedur
collect
storag
blood
futur
use
drug
free
fraction
measur
person
commun
q
solut
hold
llc
special
consider
given
pregnanc
pediatr
popul
sinc
aag
level
substanti
lower
month
postnat
pbpk
model
shown
predict
util
incorpor
aag
albumin
level
drug
bind
paramet
quantit
andor
qualit
analysi
aag
may
prove
use
biomark
diseas
diagnosi
prognosi
potenti
serv
discern
criteria
improv
likelihood
success
treatment
sinc
aag
behav
posit
apr
protein
speci
except
pig
level
increas
vari
extent
diseas
set
may
help
consid
compar
pk
healthi
versu
diseas
popul
translat
pkpd
relationship
across
speci
